The 2nd Cell Therapy Analytical Development Summit Europe was an unmissable event for Europe’s top biotech and pharma! As the cell therapy industry continues to rapidly grow and evolve, the opportunity to learn from and collaborate with leading experts in the field ensured that potency, characterisation and multi-region access, were no longer bottlenecks in the cell therapy drug development pipeline.

With FDA regulatory holds on release assays and potency forming a prevailing bottleneck in the cell therapy space, there was never a more important time for the European cell therapy community to unite to implement gold standard analytical development, effectively communicate with the EMA, and secure market approval.

Industry experts in analytical development, CMC and process development aimed to advance multi-region access, achieve consistent and scalable assay development and drive analytical standards to bring safe, high-quality cell therapies to patients across the European territories.

Our 2023 event was the only cell therapy-focused, industry-facing and European-specific summit. Attendees gained valuable insights on everything analytical development: from comparability testing to batch-to-batch variability, potency assays to regulatory considerations…and more! This allowed attendees to gain control of their manufacturing processes, assay development and analytical strategy with key thought leaders from the likes of Takeda, Novo Nordisk, Cellectis and Gadeta.

The 2nd Cell Therapy Analytical Development Summit Europe offered a competitive edge in this fast-paced industry.